المؤلفون: Peter H. Wiernik, Jacob M. Rowe, Martin S. Tallman, Jinghui Zhang, Richard C. Harvey, Krzysztof Mrózek, Hagop M. Kantarjian, Mark R. Litzow, Charles G. Mullighan, Orietta Spinelli, Kathryn G. Roberts, Jessica Kohlschmidt, Deqing Pei, Jerald P. Radich, Stanley Pounds, Ibrahim Aldoss, Alessandro Rambaldi, Ilaria Iacobucci, Wendy Stock, Cheng Cheng, Selina M. Luger, Lei Shi, Zhaohui Gu, Manuela Tosi, Clara D. Bloomfield, Marina Konopleva, I-Ming Chen, Kelly McCastlain, Stephen Kornblau, Mark D. Minden, Yongjin Li, Ravi Bhatia, Guido Marcucci, Cheryl L. Willman, Elisabeth Paietta, Debbie Payne-Turner, Marcus B. Valentine

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 35(4)

مصطلحات موضوعية: Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Pediatrics, Kaplan-Meier Estimate, Philadelphia chromosome, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Internal medicine, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Medicine, Humans, Young adult, Aged, Aged, 80 and over, ABL, business.industry, Kinase, Gene Expression Profiling, Age Factors, ORIGINAL REPORTS, Middle Aged, medicine.disease, Prognosis, Erythropoietin receptor, Gene expression profiling, Treatment Outcome, 030220 oncology & carcinogenesis, Female, business, Cytokine receptor, Tyrosine kinase, 030215 immunology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2820eca4a79823014e83dca30c1e0b87
https://pubmed.ncbi.nlm.nih.gov/27870571

المؤلفون: Stephen Pavletic, Robert Peter Gale, Mukta Arora, Vikas Gupta, Haydar Frangoul, Dan Wang, Jon J. van Rood, Pierre Tiberghien, Gregory A. Hale, Philip L. McCarthy, John T. Horan, Luis Isola, Joerg Halter, Richard T. Maziarz, Mark R. Litzow, Vijay Reddy, Olle Ringdén, Theresa Hahn, Mei-Jie Zhang, Claudio Anasetti

المساهمون: Roswell Park Cancer Institute [Buffalo], Medical College of Wisconsin, University of Minnesota System, Mayo Clinic, Vanderbilt University [Nashville], St Jude Children's Research Hospital, Department of Pharmacology, Emory University [Atlanta, GA], Mount Sinai Medical Center, Icahn School of Medicine at Mount Sinai [New York] (MSSM), Oregon Health and Science University [Portland] (OHSU), Leiden University Medical Center (LUMC), Princess Margaret Hospital, University of Toronto, University Hospital Basel [Basel], Florida Hospital Cancer Institute, Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), National Cancer Institute [Bethesda] (NCI-NIH), National Institutes of Health [Bethesda] (NIH), Karolinska University Hospital [Stockholm], Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Saas, Philippe

المصدر: Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2008, 26 (35), pp.5728-34. ⟨10.1200/JCO.2008.17.6545⟩

مصطلحات موضوعية: Male, Cancer Research, Time Factors, Graft vs Host Disease, MESH: Peripheral Blood Stem Cell Transplantation, MESH: Risk Assessment, Severity of Illness Index, 0302 clinical medicine, MESH: Risk Factors, HLA Antigens, Risk Factors, Living Donors, Cumulative incidence, MESH: Bone Marrow Transplantation, MESH: HLA Antigens, MESH: Treatment Outcome, Bone Marrow Transplantation, MESH: Living Donors, Leukemia, Histocompatibility Testing, Myeloid leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, 3. Good health, MESH: Reproducibility of Results, Europe, Leukemia, Myeloid, Acute, surgical procedures, operative, Treatment Outcome, Oncology, MESH: Young Adult, 030220 oncology & carcinogenesis, Acute Disease, MESH: Acute Disease, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, MESH: Leukemia, Myeloid, Acute, medicine.drug, Adult, medicine.medical_specialty, Canada, [SDV.IMM] Life Sciences [q-bio]/Immunology, Cyclophosphamide, Adolescent, MESH: Graft vs Host Disease, MESH: Histocompatibility Testing, Risk Assessment, 03 medical and health sciences, Myelogenous, Young Adult, MESH: Canada, Internal medicine, Acute lymphocytic leukemia, MESH: Severity of Illness Index, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, MESH: Leukemia, medicine, MESH: United States, Humans, Risk factor, Retrospective Studies, MESH: Adolescent, MESH: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Peripheral Blood Stem Cell Transplantation, MESH: Humans, business.industry, Siblings, MESH: Time Factors, Reproducibility of Results, MESH: Retrospective Studies, MESH: Adult, medicine.disease, MESH: Male, United States, MESH: Siblings, Graft-versus-host disease, MESH: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Immunology, MESH: Europe, business, MESH: Female, 030215 immunology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75ce6cde31d67cddc05777454a8f2032
https://pubmed.ncbi.nlm.nih.gov/18981462